Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab monotherapy in adolescents with moderate-to-severe atopic dermatitis
2015-004458-16Phase 3
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Dupilumab monotherapy with Placebo (2 arms). Primary endpoint: Investigator Global Assessment (IGA) response.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2015-004458-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004458-16.